61948-65-0

Usage

Uses

Used in Pharmaceutical Applications:
4-Quinazolinamine, 2-chloro-8-methoxyis used as an anti-cancer agent for its ability to inhibit the growth of cancer cells both in vitro and in animal models. Its potential as a pharmaceutical candidate is attributed to its demonstrated efficacy in combating cancer, making it a promising subject for further drug development.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Quinazolinamine, 2-chloro-8-methoxyis utilized as a building block. Its unique structure and functional groups make it a valuable component in the creation of more complex organic compounds, contributing to the advancement of synthetic chemistry.
Used in Research and Development:
4-Quinazolinamine, 2-chloro-8-methoxyis also used in research and development settings to explore its full potential in medicinal chemistry and synthetic applications. Ongoing studies aim to understand its mechanisms of action and to optimize its properties for various uses, furthering its relevance in the scientific community.

Upstream product

• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 62484-14-4 8-methoxyquinazoline-2,4-diol 
• 61948-60-5 2,4-dichloro-8-methoxy-quinazoline 

Relevant academic research and scientific papers

IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: "Z" and R1 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin-proteasome system (UPS) mediated protein degradation, endoplasmic reticulum-associated degradation (ERAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-5083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell death. In tumor bearing mice, oral administration of 71 causes rapid accumulation of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both solid and hematological tumors. 71 has been taken into phase 1 clinical trials in patients with multiple myeloma and solid tumors.

Process for preparing quinazolines

2-Halo-4-aminoquinazolines are produced by a two-step process involving cyclization of 1-phenyl-3-cyanoureas or 1-phenyl-3-cyanothioureas in the presence of phosphorus halides and phosphorus oxyhalides to provide a phosphoquinazoline intermediate which is hydrolyzed to the quinazoline. Exemplary of the process is the intramolecular cyclization of 1-(3,4-dimethoxyphenyl)-3-cyanourea in the presence of phosphorus pentachloride and phosphorus oxychloride to a phosphoquinazoline intermediate which is subsequently hydrolyzed with formic acid to 2-chloro-4-amino-6,7-dimethoxy-quinazoline. The 2-halo-4-aminoquinazolines of the instant process are particularly valuable as intermediates in the preparation of 4-amino-2-(4-substituted-piperazin-l-yl)quinazolines useful in the treatment of cardiovascular disease, e.g. hypertension.